Retraction notice to “Results from a 12 months, randomized, clinical trial comparing an olmesartan/amlodipine single pill combination to olmesartan and amlodipine monotherapies on blood pressure and inflammatin” [European Journal of Pharmaceutical Sciences 51C (2013) 26–33] (European Journal of Pharmaceutical Sciences (2014) 51 (26–33), (S092809871300345X) (10.1016/j.ejps.2013.08.031));Results from a 12 months, randomized, clinical trial comparing an olmesartan/amlodipine single pill combination to olmesartan and amlodipine monotherapies on blood pressure and inflammation

European Journal of Pharmaceutical Sciences

Volumn 51, Issue 1, 2014, Pages 26-33

  Derosa, Giuseppe ^a   Cicero, Arrigo F G ^b   Carbone, Anna ^c   Querci, Fabrizio ^d   Fogari, Elena ^a   D'Angelo, Angela ^a   Maffioli, Pamela ^a  

^a UNIVERSITY OF PAVIA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c Hospital Center of Diabetes   (Italy)

^d Ospedale Pesenti Fenaroli   (Italy)

Author keywords

Amlodipine; C reactive protein; Combination therapy; High sensitivity; Olmesartan; Omentin

Indexed keywords

AMLODIPINE; AMLODIPINE PLUS OLMESARTAN; C REACTIVE PROTEIN; CHEMERIN; GLUCOSE; INSULIN; LIPID; OLMESARTAN;

ADULT; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE REGULATION; BODY MASS; BODY WEIGHT; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DIET RESTRICTION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPERTENSION; INFLAMMATION; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; PILL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION;

AMLODIPINE; AMLODIPINE BESYLATE; AMLODIPINE BESYLATE/OLMESARTAN MEDOXOMIL; COMBINATION THERAPY; HIGH SENSITIVITY C-REACTIVE PROTEIN; OLMESARTAN; OLMESARTAN MEDOXOMIL; OMENTIN;

AMLODIPINE; ANTIHYPERTENSIVE AGENTS; BLOOD GLUCOSE; BLOOD PRESSURE; BODY MASS INDEX; BODY WEIGHT; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; FEMALE; HUMANS; HYPERTENSION; IMIDAZOLES; INFLAMMATION; INSULIN RESISTANCE; LIPIDS; MALE; MIDDLE AGED; TETRAZOLES;

EID: 84884929737     PISSN: 09280987     EISSN: 18790720     Source Type: Journal    
DOI: 10.1016/j.ejps.2018.08.039     Document Type: Erratum

References (51)

1. J. Agata, N. Ura, H. Yoshida, Y. Shinshi, H. Sasaki, M. Hyakkoku, S. Taniguchi, and K. Shimamoto Olmesartan is an angiotensin II receptor blocker with an inhibitory effect on angiotensin-converting enzyme Hypertens. Res. 29 11 2006 865 874 (Pubitemid 46062117)
2. S. Bangalore, G. Kamalakkannan, S. Parkar, and F.H. Messerli Fixed-dose combinations improve medication compliance: a meta-analysis Am. J. Med. 120 8 2007 713 719 (Pubitemid 47176510)
3. S.M. Bindom, C.P. Hans, H. Xia, A.H. Boulares, and E. Lazartigues Angiotensin I-converting enzyme type 2 (ACE2) gene therapy improves glycemic control in diabetic mice Diabetes 59 2010 2540 2548
4. K. Bozaoglu, K. Bolton, J. McMillan, P. Zimmet, J. Jowett, G. Collier, K. Walder, and D. Segal Chemerin is a novel adipokine associated with obesity and metabolic syndrome Endocrinology 148 10 2007 4687 4694 (Pubitemid 47481514)
5. A.V. Chobanian, G.L. Bakris, H.R. Black, W.C. Cushman, L.A. Green, J.L. Izzo Jr., D.W. Jones, B.J. Materson, S. Oparil, J.T. Wright Jr., E.J. Roccella, Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, National Heart, Lung, and Blood Institute, and National High Blood Pressure Education Program Coordinating Committee Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure Hypertension 42 6 2003 1206 1252 (Pubitemid 37553153)
6. S.G. Chrysant, M. Melino, S. Karki, J. Lee, and R. Heyrman The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study Clin. Ther. 30 4 2008 587 604 (Pubitemid 351680489)
7. +-pump in skeletal muscle Kidney Int. 35 1989 1 13
8. R.A. De Fronzo, J.A. Tobin, and B. Andres Glucose clamp technique, a method for quantifying insulin secretion and resistance Am. J. Physiol. 237 1979 214 223
9. C.M. De Souza Batista, R.Z. Yang, M.J. Lee, N.M. Glynn, D.Z. Yu, J. Pray, K. Ndubuizu, S. Patil, A. Schwartz, M. Kligman, S.K. Fried, D.W. Gong, A.R. Shuldiner, T.I. Pollin, and J.C. McLenithan Omentin plasma levels and gene expression are decreased in obesity Diabetes 56 6 2007 1655 1661 (Pubitemid 46842600)
10. G. Derosa, and P. Maffioli Effects of amlodipine plus atorvastatin association in hypertensive hypercholesterolemic patients Expert Rev. Cardiovasc. Ther. 8 6 2010 835 843
11. G. Derosa, and P. Maffioli Drug safety evaluation of amlodipine Expert Opin. Drug Saf. 10 5 2011 795 804
12. M. Donoghue, F. Hsieh, E. Baronas, K. Godbout, M. Gosselin, N. Stagliano, M. Donovan, B. Woolf, K. Robison, R. Jeyaseelan, R.E. Breitbart, and S. Acton A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9 Circ. Res. 87 5 2000 E1 E9
13. B. Draznin Cytosolic calcium and insulin resistance Am. J. Kidney Dis. 21 suppl. 3 1993 32 38 (Pubitemid 23180375)
14. European Diabetes Policy Group A desktop guide to type 2 diabetes mellitus Diabet. Med. 16 1999 716 730
15. E. Ferrannini, G. Buzzigoli, R. Bonadonna, M.A. Giorico, M. Oleggini, L. Graziadei, R. Pedrinelli, L. Brandi, and S. Bevilacqua Insulin resistance in essential hypertension New Engl. J. Med. 317 6 1987 350 357 (Pubitemid 17118813)
16. R. Fogari, P. Preti, A. Zoppi, A. Mugellini, L. Corradi, P. Lazzari, T. Santoro, and G. Derosa Effect of valsartan addition to amlodipine on insulin sensitivity in overweight-obese hypertensive patients Int. Med. 47 21 2008 1851 1857
17. R. Fogari, A. Zoppi, A. Mugellini, L. Corradi, P. Lazzari, P. Preti, and G. Derosa Comparative evaluation of effect of valsartan/amlodipine and atenolol/amlodipine combinations on atrial fibrillation recurrence in hypertensive patients with type 2 diabetes mellitus J. Cardiovasc. Pharmacol. 51 3 2008 217 222 (Pubitemid 351450598)
18. R. Fogari, A. Zoppi, I. Ferrari, A. Mugellini, P. Preti, and G. Derosa Time to achieve blood pressure goal with a combination versus a conventional monotherapy approach in hypertensive patients with metabolic syndrome Clin. Exp. Hypertens. 32 5 2010 245 250
19. R. Fogari, G. Malamani, L. Corradi, A. Mugellini, P. Preti, A. Zoppi, and G. Derosa Effect of valsartan or olmesartan addition to amlodipine on ankle edema in hypertensive patients Adv. Ther. 27 1 2010 48 55
20. R. Fogari, A. Zoppi, P. Maffioli, P. Lazzari, A. Mugellini, and G. Derosa Effect of telmisartan addition to amlodipine on ankle edema development in treating hypertensive patients Expert Opin. Pharmacother. 12 16 2011 2441 2448
21. R. Fogari, A. Zoppi, A. Mugellini, P. Maffioli, P. Preti, and G. Derosa Effects of valsartan or ramipril addition to amlodipine/hydrochlorothiazide combination on left ventricular mass in diabetic hypertensive patients with left ventricular hypertrophy Expert Opin. Pharmacother. 13 8 2012 1091 1099
22. R. Fogari, P. Maffioli, A. Mugellini, A. Zoppi, P. Lazzari, and G. Derosa Effects of losartan and amlodipine alone or combined with simvastatin in hypertensive patients with nonalcoholic hepatic steatosis Eur. J. Gastroenterol. Hepatol. 24 2 2012 164 171
23. W.T. Friedewald, R.I. Levy, and D.S. Fredrickson Estimation of the concentration of low density lipoprotein in plasma, without use of the preparative ultracentrifuge Clin. Chem. 18 1972 499 502
24. K.B. Goralski, T.C. McCarthy, E.A. Hanniman, B.A. Zabel, E.C. Butcher, S.D. Parlee, S. Muruganandan, and C.J. Sinal Chemerin, a novel adipokine that regulates adipogenesis and adipocyte metabolism J. Biol. Chem. 82 38 2007 28175 28188 (Pubitemid 47529521)
25. I. Hajjar, and T.A. Kotchen Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000 JAMA 290 2 2003 199 206 (Pubitemid 37430058)
26. R.J. Havel, H.A. Edr, and J.H. Bragdon The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum J. Clin. Invest. 34 1955 1345 1353
27. L.G. Heding Determination of total serum insulin (IRI) in insulin-treated diabetic patients Diabetologia 8 1972 260 266
28. S. Klose, and K. Borner Enzymatische bestimmung des gesamtcholesterins mit dem greiner selective analyzer (GSA II) J. Clin. Chem. Clin. Biochem. 15 1978 121 130 (Pubitemid 8061822)
29. S. Kralisch, J. Klein, M. Bluher, R. Paschke, M. Stumvoll, and M. Fasshauer Therapeutic perspectives of adipocytokines Expert Opin. Pharmacother. 6 2005 863 872 (Pubitemid 40946152)
30. A.H. Lichtenstein, L.J. Appel, M. Brands, M. Carnethon, S. Daniels, H.A. Franch, B. Franklin, P. Kris-Etherton, W.S. Harris, B. Howard, N. Karanja, M. Lefevre, L. Rudel, F. Sacks, L. Van Horn, M. Winston, and J. Wylie-Rosett Summary of American heart association diet and lifestyle recommendations revision 2006 Arterioscler. Thromb. Vasc. Biol. 26 2006 2186 2191 (Pubitemid 44465710)
31. D. Lloyd-Jones, R. Adams, M. Carnethon, G. De Simone, T.B. Ferguson, K. Flegal, E. Ford, K. Furie, A. Go, K. Greenlund, N. Haase, S. Hailpern, M. Ho, V. Howard, B. Kissela, and American Heart Association Statistics Committee and Stroke Statistics Subcommittee Heart disease and stroke statistics - 2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee Circulation 119 3 2009 e21 e181
32. O.A. MacDougald, and C.F. Burant The rapidly expanding family of adipokines Cell Metab. 6 2007 159 161 (Pubitemid 47324145)
33. G. Mancia, S. Laurent, E. Agabiti-Rosei, E. Ambrosioni, M. Burnier, M.J. Caulfield, R. Cifkova, D. Clément, A. Coca, A. Dominiczak, S. Erdine, R. Fagard, C. Farsang, G. Grassi, H. Haller, and European Society of Hypertension Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document J. Hypertens. 27 11 2009 2121 2158
34. D.R. Matthews, J.P. Hosker, A.S. Rudenski, B.A. Naylor, D.F. Treacher, and R.C. Turner Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man Diabetologia 28 1985 412 419 (Pubitemid 15018832)
35. S. Miura, M. Fujino, and K. Saku Angiotensin II receptor blocker as an inverse agonist: a current perspective Curr. Hypertens. Rev. 1 2005 115 121
36. S.A. Nelson, G.K. Dresser, M.K. Vandervoort, C.J. Wong, B.G. Feagan, J.L. Mahon, and R.D. Feldman Barriers to blood pressure control: a STITCH substudy J. Clin. Hypertens. (Greenwich) 13 2 2011 73 80
37. E.C. Okonofua, K.N. Simpson, A. Jesri, S.U. Rehman, V.L. Durkalski, and B.M. Egan Therapeutic inertia is an impediment to achieving the Healthy People 2010 blood pressure control goals Hypertension 47 3 2006 345 351 (Pubitemid 43740273)
38. K.L. Ong, B.M. Cheung, Y.B. Man, C.P. Lau, and K.S. Lam Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004 Hypertension 49 1 2007 69 75 (Pubitemid 46360343)
39. S. Oparil, and M. Weber Angiotensin receptor blocker and dihydropyridine calcium channel blocker combinations: an emerging strategy in hypertension therapy Postgrad. Med. 121 2 2009 25 39
40. N. Rifai, R.P. Tracy, and P.M. Ridker Clinical efficacy of an automated high-sensitivity C-reactive protein assay Clin. Chem. 45 12 1999 2136 2141
41. R.A. Santos, A.C. Simoes e Silva, C. Maric, D.M. Silva, R.P. Machado, I. de Buhr, S. Heringer-Walther, S.V. Pinheiro, M.T. Lopes, M. Bader, E.P. Mendes, V.S. Lemos, M.J. Campagnole-Santos, H.P. Schultheiss, R. Speth, and T. Walther Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas Proc. Natl. Acad. Sci. USA 100 14 2003 8258 8263 (Pubitemid 36842532)
42. A. Schäffler, M. Neumeier, H. Herfarth, A. Fürst, J. Schölmerich, and C. Büchler Genomic structure of human omentin, a new adipocytokine expressed in omental adipose tissue Biochim. Biophys. Acta 1732 1-3 2005 96 102 (Pubitemid 43267310)
43. J.R. Sowers At the cutting edge: insulin resistance and hypertension Mol. Cell. Endocrinol. 74 1990 C87 C89
44. T. Teramoto, T. Fujita, R. Kawamori, S. Miyazaki, S. Teramukai, and M. Igarashi OMEGA study: design, baseline data, metabolic syndrome prevalence in a large-scale observational study of hypertensive patients: the Olmesartan mega study to determine the relationship between cardiovascular endpoints and blood pressure goal achievement study Hypertens. Res. 31 2008 2011 2017
45. C. Tikellis, C.I. Johnston, J.M. Forbes, W.C. Burns, L.M. Burrell, J. Risvanis, and M.E. Cooper Characterization of renal angiotensin-converting enzyme 2 in diabetic nephropathy Hypertension 41 3 2003 392 397 (Pubitemid 36314606)
46. A.W. Wahlefeld Triglycerides determination after enzymatic hydrolysis H.U. Bermeyer, Methods of Enzymatic Analysis second English ed. 1974 Academic Press, Inc. New York 18 31
47. B.J. Winer Statistical Principles in Experimental Design second ed. 1971 McGraw-Hill New York
48. V. Wittamer, J.D. Franssen, M. Vulcano, J.F. Mirjolet, E. Le Poul, I. Migeotte, S. Brézillon, R. Tyldesley, C. Blanpain, M. Detheux, A. Mantovani, S. Sozzani, G. Vassart, M. Parmentier, and D. Communi Specific recruitment of antigen-presenting cells by chemerin, a novel processed ligand from human inflammatory fluids J. Exp. Med. 198 7 2003 977 985 (Pubitemid 37248614)
49. R.Z. Yang, M.J. Lee, H. Hu, J. Pray, H.B. Wu, B.C. Hansen, A.R. Shuldiner, S.K. Fried, J.C. McLenithan, and D.W. Gong Identification of omentin as a novel depot-specific adipokine in human adipose tissue: possible role in modulating insulin action Am. J. Physiol. Endocrinol. Metab. 290 6 2006 E1253 E1261
50. S.S. Yoon, Y. Ostchega, and T. Louis Recent trends in the prevalence of high blood pressure and its treatment and control, 1999-2008 NCHS Data Brief 48 2010 1 8
51. T.P. Zwacka, V. Hornbach, and J. Torzewski C-reactive protein-mediated lipoprotein uptake by macrophages Circulation 103 2001 1194 1197